BioCentury | Sep 12, 2020
Politics, Policy & Law

NIH taking action on racial disparities in Alzheimer’s research

...Nevada —were chosen to reach minority communities. The University of New Mexico...
...to bring underrepresented communities into clinical development. Danielle Golovin NIH University of New Mexico University...
BioCentury | Oct 27, 2017
Company News

UNM grants Pascal Biosciences option to VPREB1-targeted mAb for ALL

...The University of New Mexico (Albuquerque, N.M.) granted Pascal Biosciences Inc. (TSX-V:PAS) an exclusive option to gain exclusive, worldwide...
...University of New Mexico , Albuquerque, N.M. Pascal Biosciences Inc. (TSX-V:PAS), Vancouver, B.C. Business: Cancer Jaime De Leon Pascal Biosciences Inc. University of New Mexico Pre-B...
BioCentury | Jul 13, 2017
Preclinical News

IL-11 receptor inhibition tied to osteosarcoma

...metastases.\ The paper's authors included researchers from the University of Texas MD Anderson Cancer Center, University of New Mexico...
BioCentury | Apr 20, 2017
Finance

Zuckerberg’s research network

...University of California Davis , University of California San Francisco , University of Kentucky , University of New Mexico...
BioCentury | Nov 15, 2016
Distillery Techniques

Drug delivery

...doi:10.1073/pnas.1615288113 CONTACT: Richard L. Sidman, Harvard Medical School, Boston, Mass. Email: richard_sidman@hms.harvard.edu CONTACT: Wadih Arap, University Of New Mexico...
...Cancer Center, Albuquerque, N.M. email: warap@salud.unm.edu CONTACT: Renata Pasqualini, same affiliation as above email: rpasqual@salud.unm.edu Esme Gaisford University of New Mexico Heat...
BioCentury | Oct 13, 2016
Strategy

Exosomes in the zone

...to treat cancer Intrexon Corp. (NYSE:XON) April 2016 Exovita Biosciences Inc. Developing exosome-based cancer therapeutics University of New Mexico...
BioCentury | Jun 23, 2016
Translation in Brief

Musashi's dual duel

...Center, and is now an assistant professor in the department of internal medicine at the University of New Mexico...
BioCentury | Mar 31, 2016
Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)

...CONTACT: Richard L. Sidman, Harvard Medical School , Boston, Mass. e-mail: richard_sidman@hms.harvard.edu CONTACT: Wadih Arap, University of New Mexico...
BioCentury | Feb 4, 2016
Distillery Therapeutics

Therapeutics:Proprotein convertase subtilisin/kexin type 9 (PCSK9)

...Alan T. Remaley, National Institutes of Health (NIH), Bethesda, Md. e-mail: aremaley1@nhlbi.nih.gov CONTACT: Bryce Chackerian, University of New Mexico...
BioCentury | Nov 12, 2015
Distillery Therapeutics

Therapeutics: Vascular endothelial growth factor receptor 1 (FLT1; VEGFR-1); neuropilin 1 (NRP1)

...CONTACT: Richard L. Sidman, Harvard Medical School , Boston, Mass. e-mail: richard_sidman@hms.harvard.edu CONTACT: Renata Pasqualini, University of New Mexico...
Items per page:
1 - 10 of 35
BioCentury | Sep 12, 2020
Politics, Policy & Law

NIH taking action on racial disparities in Alzheimer’s research

...Nevada —were chosen to reach minority communities. The University of New Mexico...
...to bring underrepresented communities into clinical development. Danielle Golovin NIH University of New Mexico University...
BioCentury | Oct 27, 2017
Company News

UNM grants Pascal Biosciences option to VPREB1-targeted mAb for ALL

...The University of New Mexico (Albuquerque, N.M.) granted Pascal Biosciences Inc. (TSX-V:PAS) an exclusive option to gain exclusive, worldwide...
...University of New Mexico , Albuquerque, N.M. Pascal Biosciences Inc. (TSX-V:PAS), Vancouver, B.C. Business: Cancer Jaime De Leon Pascal Biosciences Inc. University of New Mexico Pre-B...
BioCentury | Jul 13, 2017
Preclinical News

IL-11 receptor inhibition tied to osteosarcoma

...metastases.\ The paper's authors included researchers from the University of Texas MD Anderson Cancer Center, University of New Mexico...
BioCentury | Apr 20, 2017
Finance

Zuckerberg’s research network

...University of California Davis , University of California San Francisco , University of Kentucky , University of New Mexico...
BioCentury | Nov 15, 2016
Distillery Techniques

Drug delivery

...doi:10.1073/pnas.1615288113 CONTACT: Richard L. Sidman, Harvard Medical School, Boston, Mass. Email: richard_sidman@hms.harvard.edu CONTACT: Wadih Arap, University Of New Mexico...
...Cancer Center, Albuquerque, N.M. email: warap@salud.unm.edu CONTACT: Renata Pasqualini, same affiliation as above email: rpasqual@salud.unm.edu Esme Gaisford University of New Mexico Heat...
BioCentury | Oct 13, 2016
Strategy

Exosomes in the zone

...to treat cancer Intrexon Corp. (NYSE:XON) April 2016 Exovita Biosciences Inc. Developing exosome-based cancer therapeutics University of New Mexico...
BioCentury | Jun 23, 2016
Translation in Brief

Musashi's dual duel

...Center, and is now an assistant professor in the department of internal medicine at the University of New Mexico...
BioCentury | Mar 31, 2016
Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)

...CONTACT: Richard L. Sidman, Harvard Medical School , Boston, Mass. e-mail: richard_sidman@hms.harvard.edu CONTACT: Wadih Arap, University of New Mexico...
BioCentury | Feb 4, 2016
Distillery Therapeutics

Therapeutics:Proprotein convertase subtilisin/kexin type 9 (PCSK9)

...Alan T. Remaley, National Institutes of Health (NIH), Bethesda, Md. e-mail: aremaley1@nhlbi.nih.gov CONTACT: Bryce Chackerian, University of New Mexico...
BioCentury | Nov 12, 2015
Distillery Therapeutics

Therapeutics: Vascular endothelial growth factor receptor 1 (FLT1; VEGFR-1); neuropilin 1 (NRP1)

...CONTACT: Richard L. Sidman, Harvard Medical School , Boston, Mass. e-mail: richard_sidman@hms.harvard.edu CONTACT: Renata Pasqualini, University of New Mexico...
Items per page:
1 - 10 of 35